Concepedia

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial

James Chih‐Hsin Yang, D. Ross Camidge, Cheng‐Ta Yang, Jianying Zhou, Renhua Guo, Chao‐Hua Chiu, Gee‐Chen Chang, Her-Shyong Shiah, Yuan Chen, Chin-Chou Wang,

Journal of Thoracic Oncology · 2020 · 156 citations · 14 references

DOIFull text

Open access

Concepts

References

14

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al. · New England Journal of Medicine · 2010 · 5.6K citations

, , +13

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · New England Journal of Medicine · 2017 · 5.3K citations · Full text

, , +16

<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram et al. · New England Journal of Medicine · 2005 · 3.9K citations · Full text

, , +15

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2016 · 3.3K citations · Full text

, , +16